| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | https://www.hindustanbiosciences.in/ | |
| Market Cap | 3.81 Cr. | |
| Enterprise Value(EV) | 5.92 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.01 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 1.14 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 3.25 | Calculated using Price: 3.72 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.03 Cr. | 10,250,800 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society. The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology). Products The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals. Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co. In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin. |
||
Company Profile
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.
The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).
Products
The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.
Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.
In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.
| 1 Day |
|
-4.86% |
| 1 Week |
|
+3.05% |
| 1 Month |
|
-12.68% |
| 3 Month |
|
-21.19% |
| 6 Month |
|
-3.63% |
| 1 Year |
|
-11.43% |
| 2 Year |
|
+238.18% |
| 5 Year |
|
+158.33% |
| 10 Year |
|
+116.28% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -7.71 | -11.47 | -19.21 | -35.60 | -10.74 | -71.30 | 5.22 | 3.67 | -52.96 | |
| Return on Capital Employed (%) | -7.32 | -10.57 | -16.78 | -30.17 | -8.37 | -49.03 | 2.68 | 2.40 | -23.70 | |
| Return on Assets (%) | -6.96 | -10.03 | -16.51 | -30.15 | -8.42 | -47.82 | 2.37 | 1.45 | -20.83 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 9 | 8 | 7 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | |
| Non Curr. Liab. | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | |
| Curr. Liab. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 10 | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 | |
| Non Curr. Assets | 8 | 8 | 7 | 5 | 5 | 3 | 4 | 3 | 2 | 2 | |
| Curr. Assets | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | |
| Misc. Exp. not W/O | 0 | 0 | |||||||||
| Total Assets | 10 | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | |
| Other Income | 0 | 0 | |||||||||
| Total Income | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | |
| Total Expenditure | -5 | -3 | -2 | -1 | -1 | -3 | -3 | -2 | -2 | -2 | |
| PBIDT | -1 | -1 | -1 | 0 | 0 | -2 | 0 | 0 | -1 | -1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | 0 | |||||||
| Exceptional Items | -2 | ||||||||||
| PAT | -1 | -1 | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 | |
| Adjusted EPS | -1 | -1 | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | |||||||
| Cash Fr. Finan. | 0 | 1 | 0 | -1 | 0 | 0 | 2 | -1 | -1 | ||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance report for 2021-22 |
|
Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Revised Annual Secretarial compliance report for 2021-22 |
|
Fri, 13 May 2022
Board Meeting Intimation for Intimation Of Board Meeting Held On 27Th May 2022 HINDUSTAN BIO SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve Intimation of Board Meeting held on 27th May 2022 |
| Fri, 20 May 2022 |
High Delivery Percentage
|
Close Crossing Last Month Low
|
High Decrease 1 Month
|
High Decrease 3 Months
|
High Increase 2 Years
|
Equities
M.F.
Sectors